Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasis
Badaró, R. ; Nascimento, C. ; Carvalho, J. S. ; Badaró, F. ; Russo, D. ; Ho, J. L. ; Reed, S. G. ; Johnson, W. D. ; Jones, T. C.
Springer
Published 1994
Springer
Published 1994
ISSN: |
1435-4373
|
---|---|
Source: |
Springer Online Journal Archives 1860-2000
|
Topics: |
Medicine
|
Notes: |
Abstract The efficacy of GM-CSF was investigated in 20 neutropenic patients (〈 1500 neutrophils/µl) with acute visceral leishmaniasis due toLeishmania chagasi. Patients were randomized to receive either GM-CSF, 5 µg/kg daily (intravenously or subcutaneously), or placebo for ten days, in combination with pentavalent antimony, 10–20 mg/kg daily for 20 days. Neutrophil counts were significantly greater on days 5 and 10 of treatment in the GM-CSF group compared with the placebo group (p〈0.02). Eosinophil and monocyte counts were also significantly increased in the GM-CSF group at day 10 (p≤0.03). Interestingly, at day 30, platelet counts were significantly higher in the GM-CSF treated group (p=0.007). Haemoglobin levels were significantly increased in the GM-CSF group on days 5 and 10 (p=0.04 and 0.02, respectively). Patients in the GM-CSF group experienced fewer secondary bacterial or viral infections than placebo patients. Infections occurred in only three patients given GM-CSF compared with eight patients given placebo (p〈0.04). All patients had complete resolution of disease symptoms at three months. Few adverse events were recorded. GM-CSF given subcutaneously at a dose of 5 µg/kg daily for ten days was well tolerated, reversed neutropenia rapidly and reduced the number of secondary infections in patients with leishmaniasis.
|
Type of Medium: |
Electronic Resource
|
URL: |